UNSPSC 51181915: Epimestrol

This classification denotes a steroidal estrogen with the molecular formula C19H26O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 7IVE3SDZ38, chemically known as 3-methoxyestra-1,3,5(10)-triene-16alpha,17alpha-diol but generally known as epimestrol, which bears US NIH Compound Identifier 23434. European Medicines Agency schedules Epimestrol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06566MIG.

UNSPSC 51181915 Epimestrol is a Commodity code that covers the supply of pharmaceutical active ingredients and finished dosage forms to state and local government healthcare facilities and programs. State and local procurement under this code focuses on generic multi-source pharmaceuticals and over-the-counter products distributed through established wholesaler networks and supplied by certified manufacturers meeting current Good Manufacturing Practices and Drug Supply Chain Security Act compliance. The issuing bodies soliciting under the code include state cooperative purchasing alliances administering statewide pharmaceutical procurement programs. Vendors responding to opportunities must establish contractual relationships with authorized wholesalers, maintain comprehensive insurance coverage including commercial general liability, and demonstrate pricing flexibility across multiple formats such as flat pricing, net price structures, or WAC-minus discounting.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, has issued the most recent representative solicitation: Request for Proposal S1070000015802 for generic multi-source pharmaceuticals and OTC products, with proposals due March 26, 2026. The RFP establishes multiple contracts for participating state and local government facilities across Minnesota and Oregon, with awarded vendors effective July 1, 2026. Vendors must supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencora), Cardinal Health, and Morris & Dickson Co., LLC—and all products must be available in the marketplace by May 15, 2026. Evaluation is weighted heavily toward price competitiveness at 75 percent, with the remaining 25 percent distributed across fixed pricing, administrative compliance, EDI capability, and agreement to a 3 percent administrative fee. The RFP does not identify specific set-aside designations or restrictions for disadvantaged enterprises in the available documentation.